Gm2 Gangliosidosis Stocks List
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 0.43 | |
TXSS | B | Texas Small Cap Equity Index ETF | 0.28 | |
IWC | B | iShares Microcap ETF | 0.09 | |
FESM | B | Fidelity Enhanced Small Cap ETF | 0.06 | |
IBBQ | D | Invesco Nasdaq Biotechnology ETF | 0.05 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Nov 15 | TSHA | Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags |
Related Industries:
Biotechnology
- Gm2 Gangliosidosis
Gm2 Gangliosidosis is a rare, inherited disorder caused by a deficiency of an enzyme called beta-hexosaminidase. This enzyme is responsible for breaking down certain fatty substances in the body called gangliosides. When the enzyme is deficient, these fatty substances accumulate in the brain and other organs, leading to a variety of neurological and physical symptoms. Symptoms of Gm2 Gangliosidosis can include seizures, developmental delays, muscle weakness, vision and hearing loss, and difficulty swallowing.
Popular Now
Recent Comments
- TraderMike on BOOT
- Dr_Duru on BOOT
- TraderMike on Stochastic Reached Oversold
- SuccessfulGrasshopper897 on Stochastic Reached Oversold
- Cos3 on Adding float as advanced filter criteria?
From the Blog
Featured Articles